Main Menu

Video: Industry partnerships in breast cancer research

Dr Rachael Natrajan heads the Functional Genomics team in the Breast Cancer Now Toby Robins Research Centre, within the Division of Breast Cancer at the ICR. She focuses on understanding the biology of breast cancers that are resistant to treatment – to identify new therapeutic targets and biomarkers for these aggressive forms of the disease.

Dr Natrajan’s work involves the use of patient-derived models of resistance to investigate the effectiveness of existing and experimental therapies. She is also exploiting cutting-edge tumour profiling technologies to identify key differences between patient breast tumours that respond differently to treatment – to develop new biomarkers of resistance.

Dr Natrajan’s team has already uncovered genomic alterations that are specific to aggressive forms of breast cancer. She is now looking to form partnerships with industry to find ways to target these with new therapies.

Our researchers in the Division of Breast Cancer work closely with industry to develop novel breast cancer treatments, in a multidisciplinary approach that ranges from clinically-relevant fundamental biology to therapy discovery. They are developing biomarkers, discovery novel drivers of cancer phenotypes and testing new therapeutic approaches in proof-of-concept clinical trials.

Watch more videos of our researchers

Working with pharmaceutical companies

Dr Marco Gerlinger talking about working with pharmaceutical companies

Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.


New partnerships in cancer epigenetics

Professor Jessica Downs

Our Epigenetics and Genome Stability team, led by Professor Jessica Downs, is working on a variety of research programmes that could be developed in collaboration with commercial partners.


Sharing experience with industry partners

Dr Paul Huang

Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.


Collaborating with commercial partners

Dr Anguraj Sadanandam

Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.


Exploring new opportunities for collaborative working

Professor Uwe Oelfke

Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.


The benefits of partnering with industry

Dr Igor Vivanco

Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.


Connections newsletter

Sign up to our new quarterly newsletter for updates on our Business and Innovation Office and news about working with industry.